Healthmatters: A Continuing Medical Education Company 

   |  About HealthmattersCME  |  CME Council  |  Contact

« Back to Resources

Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence

: Live Meeting
: 1.5 AMA PRA Category 1 Credit(s)™; 1.5 contact hours of pharmacotherapy credit for APRNs
Target Audience
: Physicians, APRNs
Expiration Date
: 11/13/2017

Read the content below to launch the activity

Please join us for an interactive, CME-certified symposium during AAO 2017:
Mechanisms of Pressure Relief in Glaucoma:
Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence

Monday, November 13, 2017
Dinner:                      6:00PM – 6:30PM
Scientific Program:   6:30 PM – 8:00 PM

Loews New Orleans Hotel
300 Poydras Street
New Orleans, LA
Louisiana Ballroom I & II

David S. Friedman, MD, MPH, PhD
Director, Dana Center for Preventive Ophthalmology
Wilmer Eye Institute
Alfred Sommer Professor of Ophthalmology
Johns Hopkins University School of Medicine
Professor, Department of International Health
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD

Steven J. Gedde, MD
John G. Clarkson Chair in Ophthalmology
Professor of Ophthalmology
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL

W. Daniel Stamer, PhD
Joseph A. C. Wadsworth Professor of Ophthalmology
Professor of Biomedical Engineering
Duke University
Durham, NC

Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.

In this CME-certified symposium, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently-approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; recommendations for single and two-drug failure, non-compliance, and new delivery systems that allow sustained medication release.

At the conclusion of this educational initiative, the participant should be better able to:

– Assess the current healthcare needs of patients with open-angle glaucoma

– Interpret the new evidence surrounding the underlying mechanism of glaucoma and the subsequent discovery of new therapies that address deficiencies in the clinical care of glaucoma

– Discuss the published findings and the clinical significance of the latest surgical techniques and MIGS devices for glaucoma, including how each may be used to achieve IOP targets for a diverse range of patients

– Describe how IOP-lowering medical therapy is changing with newly approved therapeutic agents as well as novel approaches to drug delivery that are in the pipeline.